Japanese generic drug listings for November
Japan's Ministry of Health, Labor and Welfare added 14 generic drugs from nine companies to the National Health Insurance drug price list on November 2. This is the first listing of generic drugs for this month since the twice-a-year announcement procedure was implemented in the last fiscal year.
There were no "first listing" generics this time. Three generic versions of the cancer treatment levofolinate calcium (originally Isovorin from Wyeth), two copies of the anti-allergic agent cetirizine HCl (UCB Japan's Zyrtec), and two of the antiulcerant ranitidine (GlaxoSmithKline's Zantac) were added to the list.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze